U.S. pharma giant copyright scrapped two experimental weight loss capsules past year—a when-every day pill, lotiglipron, resulting from elevated liver enzymes and a twice-day-to-day capsule, danuglipron, as a consequence of powerful Uncomfortable side effects—but CEO Albert Bourla has stated the company is decided to “Perform and acquire” i